Francesco Landi

Prof. Francesco Landi

Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart, L.go F. Vito 8, Rome, Italy
+1

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2016 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
CBCharlotte Beaudart
Charlotte Beaudart
EMEugène McCloskey
Eugène McCloskey
Olivier BruyèreOlivier Bruyère
Olivier Bruyère
Matteo  CesariMatteo Cesari
Matteo Cesari
RYRolland Yves
Rolland Yves
CCCyrus Cooper
Cyrus Cooper
Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to be accurate and reliable in investigational settings, many are not easily applied to daily practice. This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were afterwards organized for the whole group to make amendments and discuss further recommendations. This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire, the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered and involve the combination of both resistance and endurance based activity programmes with or without dietary interventions. Development of a number of pharmacological interventions is also in progress. Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future.

15 January 2013 in Age and Ageing
Verified
Journal Article
Open access
PDF file
FLFrancesco Landi
Francesco Landi
ACAlfonso J. Cruz-Jentoft
Alfonso J. Cruz-Jentoft
RLRosa Liperoti
Rosa Liperoti
ARAndrea Russo
Andrea Russo
SGSilvia Giovannini
Silvia Giovannini
GOGraziano Onder
Graziano Onder
Background and aims: sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals. We evaluated the impact of sarcopenia on the risk of all-cause death in a population of frail older persons living in community. Methods: we analysed data from the Aging and Longevity Study, a prospective cohort study that collected data on all subjects aged 80 years and older residing in the Sirente geographic area (n = 364). The present analysis was conducted among those subjects who were between 80 and 85 years of age at the time of the baseline assessment (n = 197). The main outcome measure was all-cause mortality over 7-year follow-up. According to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria, the diagnosis of sarcopenia required the documentation of low muscle mass and the documentation of either low muscle strength or low physical performance. Cox proportional regression models were used to estimate crude and adjusted hazard ratios and 95% confidence intervals of death by the presence of sarcopenia. Results: using the EWGSOP-suggested criteria, 43 subjects with sarcopenia (21.8%) were identified. During the 7-year follow-up, 29 (67.4%) participants died among subjects with sarcopenia compared with 63 subjects (41.2%) without sarcopenia (P < 0.001). After adjusting for potential confounders including age, gender, education, activities of daily living (ADL) impairment, body mass index, hypertension, congestive heart failure, chronic obstructive pulmonary disease, number of diseases, TNF-α, participants with sarcopenia had a higher risk of death for all causes compared with non-sarcopenic subjects (HR: 2.32, 95% CI: 1.01–5.43). Conclusions: our results obtained from a representative sample of very old and frail subjects show that sarcopenia is associated with mortality, independently of age and other clinical and functional variables.

22 July 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
Anna PiccaAnna Picca
Anna Picca
Riccardo CalvaniRiccardo Calvani
Riccardo Calvani
Helio Coelho-JuniorHelio Coelho-Junior
Helio Coelho-Junior
FLFrancesco Landi
Francesco Landi
RBRoberto Bernabei
Roberto Bernabei
Emanuele MarzettiEmanuele Marzetti
Emanuele Marzetti
Oxidative stress develops as a response to injury and reflects a breach in the cell’s antioxidant capacity. Therefore, the fine-tuning of reactive oxygen species (ROS) generation is crucial for preserving cell’s homeostasis. Mitochondria are a major source and an immediate target of ROS. Under different stimuli, including oxidative stress and impaired quality control, mitochondrial constituents (e.g., mitochondrial DNA, mtDNA) are displaced toward intra- or extracellular compartments. However, the mechanisms responsible for mtDNA unloading remain largely unclear. While shuttling freely within the cell, mtDNA can be delivered into the extracellular compartment via either extrusion of entire nucleoids or the generation and release of extracellular vesicles. Once discarded, mtDNA may act as a damage-associated molecular pattern (DAMP) and trigger an innate immune inflammatory response by binding to danger-signal receptors. Neuroinflammation is associated with a large array of neurological disorders for which mitochondrial DAMPs could represent a common thread supporting disease progression. The exploration of non-canonical pathways involved in mitochondrial quality control and neurodegeneration may unveil novel targets for the development of therapeutic agents. Here, we discuss these processes in the setting of two common neurodegenerative diseases (Alzheimer’s and Parkinson’s disease) and Down syndrome, the most frequent progeroid syndrome.

2 February 2017 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
OCon behalf of the SPRINTT Consortium
on behalf of the SPRINTT Consortium
Emanuele MarzettiEmanuele Marzetti
Emanuele Marzetti
Riccardo CalvaniRiccardo Calvani
Riccardo Calvani
MTMatteo Tosato
Matteo Tosato
Matteo  CesariMatteo Cesari
Matteo Cesari
FLFrancesco Landi
Francesco Landi

27 January 2016 in Nutrients
Verified
Journal Article
Open access
PDF file
FLFrancesco Landi
Francesco Landi
Riccardo CalvaniRiccardo Calvani
Riccardo Calvani
MTMatteo Tosato
Matteo Tosato
AMAnna Maria Martone
Anna Maria Martone
EOElena Ortolani
Elena Ortolani
Emanuele MarzettiEmanuele Marzetti
Emanuele Marzetti
Older people frequently fail to ingest adequate amount of food to meet their essential energy and nutrient requirements. Anorexia of aging, defined by decrease in appetite and/or food intake in old age, is a major contributing factor to under-nutrition and adverse health outcomes in the geriatric population. This disorder is indeed highly prevalent and is recognized as an independent predictor of morbidity and mortality in different clinical settings. Even though anorexia is not an unavoidable consequence of aging, advancing age often promotes its development through various mechanisms. Age-related changes in life-style, disease conditions, as well as social and environmental factors have the potential to directly affect dietary behaviors and nutritional status. In spite of their importance, problems related to food intake and, more generally, nutritional status are seldom attended to in clinical practice. While this may be the result of an “ageist” approach, it should be acknowledged that simple interventions, such as oral nutritional supplementation or modified diets, could meaningfully improve the health status and quality of life of older persons.

8 February 2017 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
OCon behalf of the SPRINTT Consortium
on behalf of the SPRINTT Consortium
Emanuele MarzettiEmanuele Marzetti
Emanuele Marzetti
Riccardo CalvaniRiccardo Calvani
Riccardo Calvani
MTMatteo Tosato
Matteo Tosato
Matteo  CesariMatteo Cesari
Matteo Cesari
FLFrancesco Landi
Francesco Landi